Tokyo – March 2025 – Dr. Taku Kambayashi, Co-Founder and Chief Scientific Advisor (CSA) of Abrax Japan and a Professor at the University of Pennsylvania, appeared on Nippon Television’s educational variety program “The world’s number one class: 2-Hour Special”, which aired on March 1, 2025, at 7:00 PM.
During the program, Dr. Kambayashi provided insights into the groundbreaking new drug “F-275,” which is under development at Abrax Japan. He discussed the discovery process, recent advancements, and future prospects for the drug.
The broadcast highlighted the latest progress based on Dr. Kambayashi’s 2021 research published in Science, as well as updates on the ongoing drug development program. Additionally, new experimental results from obesity model mice were introduced, accompanied by visual data to help viewers understand the drug’s potential.
Jo Narita, Co-Founder and CEO of Abrax Japan, commented on Dr. Kambayashi’s television appearance:
“We are honored that our research and development efforts were featured on such a prestigious program. This opportunity allowed us to share our work with a broad audience, and we are thrilled to see the high level of interest in our program. Abrax Japan is currently in the final stages of preparation for the First-in-Human clinical trials of our lead asseet, F-275. We look forward to sharing positive updates with everyone in the near future.”
Abrax Japan, Inc. was founded in 2020 based on the foundational research of Dr. Kambayashi. Together with CEO Jo Narita, they established the company in Japan to advance their discoveries.
To date, Abrax has raised a total of 550 million JPY in seed funding. The company is now planning a Series A funding round to support further drug development, manufacturing, and upcoming clinical trials.
For further inquiries, please contact us here.
